Alkem Laboratories Limited (ALKEM) share price and analysis
ALKEM last traded at ₹5,175.00 (+0.76%) on the NSE. Market cap ₹61,875 Cr (Mid cap), Pharma & Healthcare sector.
Overall rating: 5.7/10 (Average)
- Valuation: 7.1/10
- Profitability: 6.1/10
- Growth: 5.0/10
- Financial health: 8.0/10
- Price trend: 2.3/10
Long-term view: Neutral (watchlist). A mixed picture. Wait for better value or a clearer trend. Trade bias (next few weeks): Strong short. Trend and momentum are clearly pointing down.
Strengths of ALKEM
- Valuation (P/E) (P/E 29.9 vs sector 41.1): Slightly cheaper than sector peers on earnings.
- Debt / equity (0.15): Comfortable debt level.
- Net profit margin (13.2%): Healthy profit margins.
- Revenue growth (YoY) (+13.8%): Solid sales growth.
- Current ratio (2.76): Plenty of short-term assets to cover short-term bills.
- Free cash flow (1.6% FCF yield): Generates healthy free cash flow.
- Analyst target (₹5,984 (+15.6%)): 20 analysts' average target implies +15.6%, moderate upside.
- Volatility (1Y) (23% annualised): Below-average volatility.
Weaknesses of ALKEM
- 50-DMA vs 200-DMA (-3.9% gap): 50-day average is below the 200-day (death-cross setup), so medium-term momentum is down.
- Long-term trend (-4.4% vs 200-DMA): Slipped just below its 200-day average, so the trend is weakening.
- Profit growth (YoY) (-11.7%): Profits are declining.
- 6-month performance vs Nifty 50 (-5.7% vs +7.4%): Lagging the Nifty 50.
- Momentum (RSI 14) (RSI 49): Momentum is soft.
- 52-week range (13% below high): In the lower part of its 52-week range.
Key numbers
| Number | Value | Assessment | Normal range |
|---|---|---|---|
| P/E (TTM) | 29.9 | Cheaper than peers | 37.0–49.3 (sector median 41.1) |
| Forward P/E | 23.4 | Profits expected to grow | below today's P/E (29.9) and near 41 |
| Price / book | 4.16 | Normal | 2–6 |
| EPS (TTM) | ₹172.93 | Profitable | above ₹0 |
| Return on equity | 14.2% | Average | 15%+ (below 10% is weak) |
| Debt / equity | 0.15 | Low debt | below 1.0 (under 0.5 is great) |
| Net margin | 13.2% | Healthy | 10%+ (below 5% is thin) |
| Operating margin | 17.1% | Average | 20%+ strong, below 10% thin |
| Revenue growth | +13.8% | Growing well | 10%+ a year (below 3% is weak) |
| Profit growth | -11.7% | Falling | 10%+ a year (falling is weak) |
| Dividend yield | 0.39% | Small payout | 1.5%+ (none is fine for growth firms) |
| Current ratio | 2.76 | Comfortable | 1.5+ (below 1 is tight) |
| 52W high | ₹5,933.50 | 13% below · far from the high | price in the top 40% of its 52-week range |
| 52W low | ₹4,811.00 | Price is 8% above it | |
| 50-DMA | ₹5,201.03 | Price 0.5% below | price above it = short-term uptrend |
| 200-DMA | ₹5,414.65 | Price 4.4% below | price above it = long-term uptrend |
| 1Y return | -8.7% | Lagged the Nifty 50 | Nifty 50 did −0.4% |
| Beta | 0.29 | Steadier than the market | 0.8–1.3 (1 = moves with market) |
| Promoter / insider | 61.4% | Owners have a big stake | 50%+ shows owner commitment |
| Institutions | 28.6% | Moderate interest | 30%+ is strong |
| Analyst target | ₹5,983.60 | 15.6% upside · 20 analysts | 8%+ upside |
Questions about ALKEM
What is the share price of Alkem Laboratories Limited (ALKEM) today?
ALKEM last traded at ₹5,175.00 (+0.76% on the day) on the NSE. Its 52-week range is ₹4,811.00 to ₹5,933.50. Prices are delayed and come from Yahoo Finance.
Is ALKEM a good stock for the long term?
StockLens rates ALKEM 5.7 out of 10 (Average) overall. Its long-term verdict is "Neutral (watchlist)": A mixed picture. Wait for better value or a clearer trend. Strengths: cheap vs peers, low debt, high margins. Concerns: bearish moving averages, downtrend, falling profits.
Is ALKEM share overvalued?
ALKEM trades at a P/E of 29.9 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Cheaper than peers". Its price-to-book ratio is 4.16.
Is ALKEM good for short-term trading?
The trade bias for the next few weeks is "Strong short": Trend and momentum are clearly pointing down. The price is 4.4% below its 200-day average and 14-day RSI is 49.
Which stocks are similar to ALKEM?
Similar Pharma & Healthcare stocks of comparable size include Biocon, Glenmark Pharmaceuticals, Lupin, Max Healthcare, Aurobindo Pharma. You can compare up to 4 of them side by side on StockLens.
About Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.
Stocks similar to ALKEM
- Biocon share price
- Glenmark Pharmaceuticals share price
- Lupin share price
- Max Healthcare share price
- Aurobindo Pharma share price
- Cipla share price
Compare ALKEM with BIOCON, GLENMARK, LUPIN
Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.